Effect of letrozole on the lipid profile in postmenopausal women with breast cancer

European Journal of Cancer

Volumn 37, Issue 12, 2001, Pages 1510-1513

  Elisaf, M S ^a   Bairaktari, E Th ^a   Nicolaides, C ^a   Kakaidi, B ^a   Tzallas, C S ^a   Katsaraki, A ^a   Pavlidis, N A ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Aromatase inhibitor; Cholesterol; Letrozole; Lipid parameters; Triglycerides

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LETROZOLE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TAMOXIFEN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DRUG ACTIVITY; DRUG EFFECT; FEMALE; HORMONAL THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR;

AGED; ANTINEOPLASTIC AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; APOLIPOPROTEINS E; BREAST NEOPLASMS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; ENZYME INHIBITORS; FEMALE; HUMANS; LIPIDS; LIPOPROTEIN(A); MIDDLE AGED; NITRILES; POSTMENOPAUSE; RISK FACTORS; TRIAZOLES; TRIGLYCERIDES;

EID: 0034885923     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00155-1     Document Type: Article

References (18)

1. Endocrine treatment of breast cancer in women
2. Molecular action and clinical relevance of aromatase inhibitors
3. Mechanisms of action of endocrine treatment in breast cancer
4. Aromatase, its inhibitors and their use in breast cancer treatment
5. The efficacy of CGS20267 in suppressing oestrogen biosynthesis in patients with advanced stage breast cancer
6. Open dose-finding study of a new potent and selective non-steroidal aromatase inhibitor, CGS20267, in healthy male subjects
7. Femara (CGS20267): A Phase I study of a new potent oral aromatase inhibitor of breast cancer
8. Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma
9. Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5mg daily, 0.5mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer
10. The beneficial effect of tamoxifen on serum lipoprotein A levels: An additional anti-atherogenic property
11. Status of aromatase inhibitors in relation to other breast cancer treatment modalities
12. Aromatase inhibitors and their use in the sequential setting
13. Do LH-RH analogues induce effects similar to tamoxifen on serum lipid parameters in premenopausal women with breast cancer? A prospective study
14. Relation of high- density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience)
15. Efficacy of lipid profiles in prediction of coronary disease
16. Risk versus benefits in the clinical application of aromatase inhibitors
17. Tamoxifen decreases serum cholesterol by inhibiting cholesterol synthesis
18. Tamoxifen and toremifen lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer